Evidence map›Paper›PMID 33073770›Full record

ArticleBiomolecules & therapeutics2020

Novel SIRT Inhibitor, MHY2256, Induces Cell Cycle Arrest, Apoptosis, and Autophagic Cell Death in HCT116 Human Colorectal Cancer Cells.

Min Jeong Kim, Young Jung Kang, Bokyung Sung, Jung Yoon Jang, Yu Ra Ahn, Hye Jin Oh, Heejeong Choi, Inkyu Choi, Eunok Im, Hyung Ryong Moon and 2 more

Open access · greenAbstract read
In one paragraph

Article in Biomolecules & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Roles of NADInternational journal of molecular sciences · 2022
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Autophagy Modulators in Cancer Therapy.International journal of molecular sciences · 2021
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Min Jeong KimDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Young Jung KangDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Bokyung SungDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Jung Yoon JangDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Yu Ra AhnDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Hye Jin OhDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Heejeong ChoiDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Inkyu ChoiDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Eunok ImDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Hyung Ryong MoonDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Hae Young ChungDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Nam Deuk KimDivision of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Pusan National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined the anticancer effects of a novel sirtuin inhibitor, MHY2256, on HCT116 human colorectal cancer cells to investigate its underlying molecular mechanisms. MHY2256 significantly suppressed the activity of sirtuin 1 and expression levels of sirtuin 1/2 and stimulated acetylation of forkhead box O1, which is a target protein of sirtuin 1. Treatment with MHY2256 inhibited the growth of the HCT116 (

Indexed as

ApoptosisAutophagyCell cycle arrestColorectal cancer cellsMHY2256SIRT inhibitor

Identifiers

PMID33073770
PMCPMC7585637
OpenAlexW3092878531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.